ArticleJournal of translational medicine2026
Mechanism of ASIC4 in regulating MHC-I-mediated immune evasion in pancreatic cancer.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmune evasion is a major cause of the poor efficacy of therapies for pancreatic ductal adenocarcinoma (PDAC). However, the underlying mechanism by which MHC-I downregulation leads to low infiltration of cytotoxic T lymphocytes in PDAC remains incompletely elucidated. This study aims to identify the molecules responsible for the low expression of MHC-I and potential novel therapeutic targets, thereby providing a theoretical foundation for reversing immune evasion in pancreatic cancer.
methodsBioinformatic analysis identified the acid-sensing ion channel (ASIC4) as a key factor associated with low cytotoxic T lymphocyte (CTL) infiltration in pancreatic ductal adenocarcinoma (PDAC). The correlation between ASIC4 expression and patient prognosis was analyzed via immunohistochemistry (IHC). To elucidate the molecular mechanism by which ASIC4 mediates immune evasion in PDAC, we comprehensively utilized Western blotting, co-immunoprecipitation, and immunofluorescence. An orthotopic PDAC mouse model was established to assess the impact of ASIC4 deletion on CD8⁺ T cell infiltration and tumor growth in vivo.
resultsThe study found that in pancreatic ductal adenocarcinoma (PDAC), the expression of ASIC4 was significantly upregulated and negatively correlated with the low expression of Major Histocompatibility Complex class I (MHC-I), which was associated with poor patient prognosis. Notably, knocking down ASIC4 led to a significant increase in CD8+ T cell infiltration and slowed tumor growth in vivo. Mechanistic investigations revealed that ASIC4 knockdown restored total and surface levels of MHC-I by inhibiting its autophagic-lysosomal degradation.
conclusionThis study revealed that ASIC4 is highly expressed in PDAC, and its elevated expression is significantly associated with poor prognosis in pancreatic cancer patients. Further mechanistic investigations demonstrated that ASIC4 promotes the degradation of MHC-I via the lysosomal pathway. The subsequent reduction in MHC-I expression leads to decreased infiltration of cytotoxic T lymphocytes (CTLs), ultimately accelerating pancreatic cancer progression. Silencing ASIC1 restored MHC-I expression and enhanced the antitumor efficacy of CD8⁺ T cells. These findings identify ASIC4 as a potential therapeutic target and provide a theoretical foundation for reversing the immune-cold phenotype of PDAC and developing combined immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.